The European Medicines Agency (EMA) has recommended the approval of Lecanemab, an antibody that may slow the progression of Alzheimer’s disease, specifically for patients with light cognitive impairment and minimal risk factors. This marks the first EU endorsement targeting the…
The European Medicines Agency (EMA) has partially approved Leqembi (lecanemab) for patients with mild cognitive decline or mild dementia due to Alzheimer’s disease, reversing a prior rejection. The treatment is now authorized for those with a lower risk of adverse…
Music has emerged as a powerful tool for enhancing communication among individuals with autism and Alzheimer’s disease. Families like that of 9-year-old Édouard, who is autistic, have discovered that singing transforms daily interactions and fosters connections. His mother recounts how…
